MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/bf01682343

Медицинская библиотека · Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 1996

The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.

Harvey HA, Lipton A

Перевод в очереди

Аннотация

Frequent complications of bone metastases include pain, pathologic fracture, hypercalcemia and spinal cord compression. Lytic bone metastases result from excessive activation of osteoclasts by tumor-produced cytokines. Aredia (pamidronate) is a potent bisphosphonate that inhibits osteoclast activation. In two dose-seeking phase I trials in patients with breast cancer and prostate cancer, repeated intravenous infusion of Aredia was shown to be safe and effective in reducing bone resorption and pain. In a randomized phase III trial of 377 patients with multiple myeloma, Aredia was administered in a dosage of 90 mg i.v. every 4 weeks. Compared with placebo, treatment with Aredia was associated with a significant decrease in bone pain and in the incidence and time to development of all skeleton-related events. Data from two phase III breast cancer trials each involving 300 patients are now being analyzed. The newer bisphosphonates can safely be used together with standard anticancer therapy to provide effective palliation of symptoms caused by lytic bone metastases.

Для цитирования: Harvey HA, Lipton A. The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 1996. DOI: 10.1007/bf01682343.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.